p38 MAP Kinase Mediates Nitric Oxide-induced
Apoptosis of Neural Progenitor Cells*
Aiwu
Cheng
,
Sic L.
Chan
,
Ollivier
Milhavet
,
Shuqin
Wang
, and
Mark P.
Mattson
§¶
From the
Laboratory of Neurosciences, National
Institute on Aging Gerontology Research Center, Baltimore, Maryland
21224 and the § Department of Neuroscience, Johns Hopkins
University School of Medicine, Baltimore, Maryland 21205
Received for publication, August 10, 2001, and in revised form, September 6, 2001
 |
ABSTRACT |
Neural progenitor cells (NPC) can proliferate,
differentiate into neurons or glial cells, or undergo a form of
programmed cell death called apoptosis. Although death of NPC occurs
during development of the nervous system and in the adult, the
underlying mechanisms are unknown. Here we show that nitric oxide (NO)
can induce death of C17.2 NPC by a mechanism requiring activation of
p38 MAP kinase, poly(ADP-ribose) polymerase, and caspase-3. Nitric
oxide causes release of cytochrome c from mitochondria, and
Bcl-2 protects the neural progenitor cells against nitric oxide-induced
death, consistent with a pivotal role for mitochondrial changes in
controlling the cell death process. Inhibition of p38 MAP kinase by
SB203580 abolished NO-induced cell death, cytochrome c
release, and activation of caspase-3, indicating that p38 activation serves as an upstream mediator in the cell death process. The anti-apoptotic protein Bcl-2 protected NPC against nitric oxide-induced apoptosis and suppressed activation of p38 MAP kinase. The ability of nitric oxide to trigger death of NPC by a mechanism involving p38
MAP kinase suggests that this diffusible gas may regulate NPC fate in
physiological and pathological settings in which NO is produced.
 |
INTRODUCTION |
Neural progenitor cells
(NPC)1 can give rise to both
neurons and glial cells during development of the nervous system (1). Populations of NPC are also present in certain regions of adult mammalian nervous systems where they are believed to serve as cellular
reservoirs to replace neurons and glia that die during aging or as the
result of tissue injury (2, 3). The mechanisms that control the
proliferation and differentiation of NPC (neurogenesis) are beginning
to be identified and include neurotrophic factor and cytokine signaling
pathways. For example, epidermal growth factor and basic fibroblast
growth factor promote the self-renewal of various primary and
immortalized NPC (4), and Notch and Numb signaling may play widespread
roles in controlling neural stem cell fate (5-8). In contrast to the
rapidly accumulating data on signaling mechanisms that regulate
differentiation of NPC, very little is known of the signals that
determine whether NPC live or die. This is despite the fact that
considerable death of NPC occurs during development of the nervous
system (1, 9-11) as well as in the adult nervous system in the process
of NPC turnover (12, 13). Recent findings suggest that NPC may undergo
a form of programmed cell death called apoptosis in which DNA damage
(14), release of cytochrome c from mitochondria (15), and
activation of members of the caspase family of proteases (13, 16) play
important roles.
Nitric oxide (NO) is an intra- and intercellular signaling molecule
which plays important roles in regulating synaptic plasticity and cell
survival in the adult nervous system in both physiological and
pathological settings (17, 18). Roles for NO in the development of the
nervous system are suggested from studies showing that NO can regulate
neurite outgrowth (19, 20) and synaptogenesis (21, 22). Interestingly,
NO can also induce apoptosis of a variety of types of cultured cells
including neurons (23-25) and may contribute to the death of neurons
in several disorders including ischemic stroke (26) and Alzheimer's
disease (27). As evidence, nNOS-deficient mice exhibit significant
protection against cerebral ischemia (28) and
N-methyl-D-asparatate-mediated
excitotoxicity (29, 30). The cytotoxic effects of NO may result from
its interaction with the superoxide anion to form peroxynitrite and other reactive oxygen radicals (29, 31-37). Oxidative damage to
cellular proteins and nucleic acids can, in turn, trigger an apoptotic
cascade involving activation of poly(ADP-ribose) polymerase (PARP),
mitochondrial membrane permeability transition, and release of
cytochrome c, and activation of caspases that execute the
cell death process (25, 38-43). Several different protein kinases have
been reported to act at one or more steps in the apoptotic pathway,
with c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein
(MAP) kinase being two prominent examples (44-46). It was recently
reported that p38 MAP kinase can induce translocation of the
proapoptotic protein Bax from the cytosol to mitochondria in mature
neurons undergoing NO-induced apoptosis (47).
Although NO is a prominent messenger in the brain, its effects on NPC
are unknown. To determine whether NO regulates NPC survival or death
and to explore the underlying mechanisms, we examined the effects of NO
on C17.2 cells, a clonal line of NPC that can differentiate into
neurons or glia when co-cultured with primary neurons or transplanted
into the adult rodent brain (48, 49). Our data demonstrate that NO can
induce apoptotic death of NPC by a p38 MAP kinase-
dependent mechanism: p38 MAP kinase acts at early step
prior to dysfunction of mitochondria and caspase activation, and
overexpression of Bcl-2 significantly attenuates the activation of p38
MAP kinase and protects the NPC against NO-induced death. These
findings suggest roles for NO in regulating NPC fate in physiological
and pathological settings.
 |
EXPERIMENTAL PROCEDURES |
Culture and Experimental Treatment of Neural Progenitor
Cells--
The C17.2 NPC line (a generous gift from C. Cepko) was
maintained in plastic culture flasks in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (Life Technologies, Inc.) and
5% horse serum (Life Technologies, Inc.) in a humidified atmosphere of
5% CO2, 95% air at 37 °C. For experimental
analyses, cells were grown on poly-L-lysine-coated culture
dishes or glass coverslips. Experimental treatments included: sodium
nitroprusside (SNP) and 3-aminobenzamide (Sigma) which were prepared as
200-500 × stocks in culture medium; zVAD-fmk (Biomol Research
Labs, Inc.) and SB 203580 (Sigma), which were prepared as 500 × stocks in dimethyl sulfoxide. Treatments were administered by direct
dilution into the culture medium, and an equivalent volume of vehicle
was added to control cultures.
Assessment of Cell Survival and Apoptosis--
After exposure to
experimental treatments, cells were fixed in 4% paraformaldehyde in
PBS for 30 min at room temperature and then washed with PBS. Cells were
then either stained with the DNA-binding dye Hoechst 33258 (5 µg/ml
in PBS for 2 h at room temperature or overnight at 4 °C) or
membranes were permeabilized with 0.2% Triton X-100 and the cells were
stained with propidium iodide (5 µg/ml for 10 min at room
temperature). Coverslips were mounted onto glass slides and examined
under epifluorescence illumination using a ×40 objective lens. Cells
were considered "apoptotic" if their nuclear chromatin was
condensed or fragmented, whereas cells were considered viable if their
chromatin was diffuse and evenly distributed throughout the nucleus. In
preliminary studies we determined the integrity of the plasma membrane
by staining cells with the dye trypan blue. Essentially no cells were
stained with trypan blue (data not shown), indicating that the cells
with condensed and fragmented nuclei have intact membranes and were therefore not undergoing necrosis.
Immunoblot Analysis--
After experimental
treatment the cells (~2 × 106 cells) were
solubilized in SDS-polyacrylamide gel electrophoresis sample buffer, and the protein concentration in each sample was determined using a
Bio-Rad protein assay kit with bovine serum albumin as the standard. Proteins (50 µg of protein per lane) were then resolved on 7.5-12% SDS-polyacrylamide gels and electrophoretically transferred to a
nitrocellulose membrane. Membranes were blocked with 10% nonfat milk
in TBST (Tris-HCl based buffer with 0.2% Tween 20, pH 7.5), and then
incubated for 2 h in the presence of primary antibody. Cells were
then incubated for 1 h in the presence of a 1:5000 dilution of
secondary antibody (IgG) conjugated to horseradish peroxidase. Reaction
product was visualized using an Enhanced Chemiluminescence (ECL)
Western blot detection kit (Amersham Pharmacia Biotech, United
Kingdom). The primary antibodies included anti-PARP (mouse, 1:1000,
PharMingen, San Diego, CA), anti-caspase-3 (rabbit, 1:1000,
PharMingen), anti-tubulin (mouse, 1:5000, Sigma), anti-phospho-p44/42 MAP kinase (mouse, 1:1000, New England Biolabs), and anti-p44/42 MAP
kinase (rabbit, 1:1000, New England Biolabs), anti-phospho-p38 MAP
kinase (mouse, 1:1000), anti-p38 MAP kinase (rabbit, 1:1000, Cell
Signaling, Inc.), anti-phospho-JNK (mouse, 1:1000, Santa Cruz
Biotechnology), anti-JNK (rabbit, 1:1000, Santa Cruz Biotechnology), anti-Bcl-2 (rabbit, 1:1000, StressGen, Inc.), and anti-cytochrome c (mouse, 1:1000, PharMingen).
Caspase Activity Assays--
Caspase-3 activity was assessed by
two methods. First, the extent of cleavage of procaspase-3 into the
truncated active caspase-3 fragments, and the extent of cleavage of the
caspase-3 substrate PARP, was determined by immunoblot analysis.
Second, to localize activated caspase-3 in situ, a protocol
that employs biotinylated DEVD, a pseudosubstrate and inhibitor of
caspase-3 was used (50). At designated time points following exposure
of cells to experimental treatments, they were exposed for 10 min to
Locke's buffer containing 0.01% digitonin. Cells were then incubated
for 20 min in the presence of 10 µg/ml DEVD-biotin (Calbiochem),
washed three times with PBS, and fixed for 30 min in a cold solution of
4% paraformaldehyde in PBS. Cells were incubated for 5 min in PBS
containing 0.2% Triton X-100, followed by a 30-min incubation in PBS
containing 5 µg/ml Oregon Green streptavidin (Molecular Probes,
Inc.). Cells were then washed twice with PBS and images of fluorescence
corresponding to conjugates of activated caspase-3 with DEVD-biotin
were acquired using a confocal laser scanning microscope (Zeiss CSLM
510, Germany) with excitation at 488 nm and emission at 510 nm.
Evaluation of Cytochrome c Release from Mitochondria--
Two
methods were used to determine the release of cytochrome c
from mitochondria. The first method involved confocal imaging of cells
double-labeled with Mitotracker Red CMX Ros (Molecular Probes, Inc.)
and a cytochrome c antibody. After experimental treatment,
cells were incubated with 100 nM Mitotracker Red CMX Ros
for 30 min at 37 °C (the dye is taken up by mitochondria where it
forms thiol conjugates with peptides and is thereby trapped in the
mitochondria), washed with PBS, and fixed with 4% paraformaldehyde in
PBS at 37 °C for 30 min. Fixed cells were permeabilized with 0.1%
Triton X-100 for 5 min at 4 °C, followed by a 2-h incubation at room
temperature in blocking solution (2% normal goat serum, 0.1% Triton
X-100 in PBS, pH = 7.4) containing primary monoclonal cytochrome
c antibody (10 µg/ml, PharMingen, San Diego, CA). After washing, cells were incubated for 2 h in PBS containing
fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:100,
ImmunoResearch Laboratory). Cells were then imaged in dual-scan mode on
a Zeiss CLSM 510 confocal microscope using a ×40 water immersion
objective (N.A. = 1.4). The excitation and emission wavelengths for
Mitotracker CMX Ros were 510 and 590 nm, respectively, and for
fluorescein isothiocyanate were 488 and 510 nm, respectively. The
second method involved immunoblot analysis of cytochrome c
in cytosolic and mitochondrial fractions of cells. At designated time
points following exposure to experimental treatments, cells (~1 × 107) were trypsinized and then washed with ice-cold
buffer A (250 mM sucrose, 20 mM HEPES-KOH, 1 mM EDTA, 1 mM EGTA, 2 µg/ml leupeptin, and 1 µg/ml pepstatin, pH 7.4). Cells were resuspended in 200 µl
of buffer A and carefully homogenized using a Dounce homogenizer. The
homogenates were separated into cytosol (supernatant) and mitochondrial
fractions (pellet) by differential centrifugation. Cytosolic (300 µg)
and mitochondrial (50 µg) proteins were then subjected to immunoblot
analysis using a monoclonal cytochrome c antibody as
described above.
Transient Transfection Assay--
Two expression plasmids were
employed for transient transfections: the pBabe Puro vector (5.1 kilobase) contained the complete coding sequence of human Bcl-2
cDNA (a generous gift from D. Bredesen) and the pEGFT-N1 plasmid
contained the green fluorescence protein (GFP) cDNA
(CLONTECH). Cells were transfected with 5 µg of
pBabe-Puro-Bcl-2 plasmid or co-transfected with 5 µg of pEGFP-N1
plasmid using LipofectAMINE Plus reagent (Life Technologies, Inc.)
according to the instructions of the manufacturer. Experiments were
performed 24 h after transfection.
 |
RESULTS |
NO Induces Caspase Activation and Nuclear DNA Damage in Neural
Progenitor Cells--
To determine the possible involvement of NO in
the regulation of NPC survival, we exposed C17.2 cells to increasing
concentrations of the NO donor SNP and quantified the percentage
of cells exhibiting apoptotic morphological alterations and nuclear
chromatin condensation/fragmentation (Fig.
1A). Essentially no cell death
occurred in control cultures or cultures exposed to 50 µM
SNP (Fig. 1B). However, at concentrations from 100 to 400 µM SNP induced cell death in a concentration- and
time-dependent manner such that ~50 and 70% of the cells
were killed within 10 h of exposure to 200 µM and
500 µM SNP, respectively (Fig. 1B).
Essentially all cells with apoptotic morphologies excluded trypan blue
indicating that their plasma membranes were intact and that they were
therefore not necrotic (data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 1.
Nitric oxide induces death of C17.2 neural
progenitor cells. A, cells were exposed for 7 h to
vehicle (Control) or 200 or 500 µM SNP. Cells were then
stained with the fluorescent DNA-binding dye Hoechst 33258;
phase-contrast micrographs (upper panels) and images of
Hoechst fluorescence (lower panels) of representative
microscope fields are shown. B, cells were exposed for the
indicated time periods to the indicated concentrations of SNP and the
percentage of cells that were dead in each culture were determined.
Values are the mean and S.E. of determinations made in four to six
cultures.
|
|
We next assessed caspase activity levels by performing immunoblot
analyses of lysates from cells that had been exposed to SNP for
increasing time periods. The blots were probed using antibodies against
caspase-3 and the capsase-3 substrate, PARP. SNP induced cleavage of
procaspase-3 into the active form of caspase-3, with cleavage of
procaspase-3 occurring within 4 h of exposure to SNP (Fig.
2A). When cells were treated
with the caspase inhibitor zVAD-fmk, cleavage of procaspase-3 was
largely prevented (Fig. 2A). SNP also induced PARP cleavage
which was evident within 4 h (Fig. 2C). To further
examine caspase-3 activity, we exposed cells to SNP for 4, 7, or
10 h and then processed the cells for in situ
localization of activated caspase-3 using a previously described
protocol in which DEVD-biotin is introduced into cells and then
detected with fluorescein-tagged avidin. Levels of activated caspase-3
were markedly increased in cells within 4 h of exposure to SNP and
remained elevated at 7 h (Fig. 2B). The activated
caspase-3 was localized mainly to cytoplasmic compartments at the 4-h
time point, but was also present in the nucleus at the 7-h time point. Treatment of cells with zVAD-fmk largely prevented SNP-induced caspase-3 activation.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 2.
Nitric oxide induces caspase 3 activation and
proteolytic cleavage of PARP in neural progenitor cells.
A, cells were exposed to 200 µM SNP for 4, 7, or 10 h in the absence (left) or presence
(right) of 50 µM zVAD-fmk (additional cultures
were left untreated (0 time point)). Proteins in cell lysates were
separated by electrophoresis and subjected to immunoblot analysis using
antibodies against caspase-3 or tubulin. Note that SNP induced cleavage
of caspase-3, which was largely prevented by treatment with zVAD-fmk.
B, subcellular localization of activated caspase-3 in NPC
after exposure to SNP. Confocal laser scanning microscope images
showing fluorescence corresponding to activated caspase-3 bound to the
substrate DEVD. Cultures had been left untreated (control),
or exposed to 200 µM SNP for the indicated time periods
in the absence or presence of 50 µM zVAD-fmk.
C, cells were exposed to 200 µM SNP for 4, 7, or 10 h, or were left untreated (0 time point). Proteins in cell
lysates were separated by electrophoresis and subjected to immunoblot
analysis using a PARP antibody. Note that SNP induced cleavage of
PARP.
|
|
NO-induced Death of NPC Involves Release of Cytochrome c from
Mitochondria--
Recent studies have established a mechanism for
activation of caspase-3 that involves mitochondrial alterations that
result in release of cytochrome c into the cytosol where it
forms a complex with Apaf-1 and caspase-9 resulting in caspase-9
activation which then cleaves and activates caspase-3 (51). To
determine whether NO induces cytochrome c release from
mitochondria in NPC, we performed double labeling confocal fluorescence
imaging using the mitochondrial marker dye Mitotracker red in
combination with immunostaining with an antibody against cytochrome
c. In untreated control cells, cytochrome c
immunoreactivity was co-localized with Mitotracker red fluorescence
indicating that the cytochrome c was confined to
mitochondria (Fig. 3A). After
exposure to SNP, many cells exhibited cytochrome c
immunoreactivity diffusely distributed throughout the cytoplasm and a
decrease in mitochondria-associated cytochrome c
immunoreactivity indicating that cytochrome c was released
from mitochondria (Fig. 3A). Whereas no cells (zero of 1000 cells examined in three separate cultures) exhibited this cytochrome
c release pattern in control cultures, 29 + 5% of the cells
exhibited cytochrome c release in cultures that had been
exposed for 4 h to 200 µM SNP. We next isolated
mitochondrial and cytosolic fractions from control and SNP-treated
cells and performed immunoblot analyses to determine the relative
content of cytochrome c in mitochondria versus
the cytoplasm. In the absence of SNP, cytochrome c was present at high levels in the mitochondrial fraction and was not detected in the cytoplasm (Fig. 3B). SNP caused a
progressive decrease in the amount of cytochrome c present
in the mitochondrial fraction, and a corresponding increase in the
amount of cytochrome c in the cytosolic fraction (Fig.
3B).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 3.
Nitric oxide induces cytochrome c
release from mitochondria in neural progenitor cells by a
mechanism requiring membrane permeability transition pore
formation. A, confocal laser scanning microscope images
showing Mitotracker red fluorescence (red), cytochrome
c immunoreactivity (green), and merged images
(yellow indicates sites of co-localization) in NPC cells.
The cells were either untreated (control) or exposed to 200 µM SNP for 4 h. Note localization of cytochrome
c in mitochondria in all NPC in control cultures and in some
cells in SNP-treated cultures, and diffuse localization of cytochrome
c in the cytoplasmic compartment of some NPC in SNP-treated
cultures (arrows). B, cells were exposed to 200 µM SNP for 4, 7, or 10 h. Mitochondrial and
cytosolic fractions of the cells were prepared and 300 µg of protein
were subjected to immunoblot analysis using a cytochrome c
antibody. Note that SNP induced cytochrome c release from
mitochondria.
|
|
NO Induces p38 MAP Kinase Activation, but Does Not Activate JNK,
ERK-1, and ERK-2--
Mitogen-activated protein (MAP) kinases function
in a variety of signal transduction pathways and play important roles
in regulating cell growth, differentiation, and programmed cell death. Members of the MAP kinase family include the extracellular
signal-regulated kinases (ERK-1 or p42 MAP kinase; and ERK-2 or p44 MAP
kinase), JNK, and p38 MAP kinase (52). ERKs are typically activated by growth factor stimulation whereas JNK and p38 MAP kinases are strongly
activated by a variety of cellular stresses including ultraviolet
radiation, hyperosmolarity, heat shock, and proinflammatory cytokines.
p38 MAP kinase and JNK have recently been shown to be involved in cell
death induced by nerve growth factor deprivation in a neuronal cell
line (53). In addition, p38 MAP kinase and JNK activities are also
implicated in developmental neuronal cell death, and in cell death
associated with axotomy (54, 55). We therefore determined whether one
or more of these kinases was phosphorylated and activated in response
to NO in NPC. Exposure of cells to SNP resulted in a marked (~5-fold)
increase in the level of phosphorylated p38 MAP kinase within 1 h
with a further increase in phospho-p38 MAP kinase levels by 4 h;
the increase in phospho-p38 MAP kinase occurred without a change in the
overall level of p38 MAP kinase protein during the 4-h period of
exposure to SNP (Fig. 4). In contrast,
SNP treatment did not affect phosphorylation of JNK, ERK-1, or ERK-2
during a 4-h exposure period (Fig. 4). In an additional experiment in
which cells were treated for 12 h with SNP, increased
phosphorylation of p38 MAP kinase was evident, whereas there was no
change in the phosphorylation of JNK, ERK-1, and ERK-2 (data not
shown).

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 4.
The nitric oxide donor, SNP selectively
activates p38 MAP kinase in neural progenitor cells. Cells were
treated with 500 µM SNP, and protein extracts were
prepared at the indicated time points to assess the activation of p38
MAP kinase, JNK, Erk1, and Erk2. Level of total (p38, JNK, Erk1, and
Erk2) and phosphorylated MAP kinase (pp38, p-JNK, p-Erk1, and p-Erk2)
were determined by Western blotting using specific antibodies.
Arrows indicate the position of specific immunoreactive
bands corresponding to distinct isoforms of JNK and Erk.
|
|
Activation of PARP, Caspases, and p38 MAP Kinase Are Each Required
for NO-induced Death of NPC--
To determine whether caspase
activation, PARP activity, and/or p38 MAP kinase activation are
required for NO-induced death of NPC, we pretreated cells with a
cell-permeant caspase inhibitor (zVAD-fmk), an inhibitor of PARP
(3-aminobenzamide) (56, 57), or an inhibitor of p38 MAP kinase (SB
203580) (58). Preliminary studies showed that none of the three
inhibitors affected cell viability under basal culture conditions (data
not shown). Cell death caused by SNP was significantly attenuated in
cells pretreated with zVAD-fmk, 3-aminobenzamide, and SB 203580 (Fig.
5). At a dose of 500 µM SNP
that killed 50% of the cells within 7 h, ~25% of the cells
were killed in the presence of zVAD-fmk or 3-aminobenzamide, and only
15% of the cells were killed in the presence of SB 203580. A combined
treatment with zVAD-fmk and 3-aminobenzamide provided no additional
protection beyond that obtained with either compound alone, whereas a
combined treatment with zVAD-fmk and SB 203580 resulted in additive
protection such that only 6% of the cells were killed (Fig. 5). Cell
death was prevented, and not just delayed, as the high level of
survival was maintained beyond 24 h in the presence of both
SB203580 and zVAD-fmk (data not shown). These data suggest that PARP,
p38 MAP kinase, and caspases each play essential roles in NO-mediated
death of NPC.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibitors of capasases, PARP, and p38 MAP
kinase protect neural progenitor cells against nitric oxide-induced
death. Cells were pretreated for 1 h with the indicated
concentrations of the caspase inhibitor zVAD-fmk, the PARP inhibitor
3-aminobenzamide (3-AB), and the p38 MAP kinase
inhibitor SB203580. Cells were then exposed to SNP or vehicle as
indicated and cell death was quantified 7 h later. Values are the
mean and S.E. of determinations made in at least 4 cultures. *,
p < 0.01; **, p < 0.001 compared with
value for cells exposed to SNP alone (ANOVA with Scheffe post-hoc
tests).
|
|
p38 MAP Kinase Acts at a Premitochondrial Step in Nitric
Oxide-induced NPC Apoptosis--
The data to this point demonstrated a
requirement for p38 MAP kinase in nitric oxide-mediated death of NPC,
but did not establish where in the apoptotic cascade p38
MAP kinase acted. To determine whether p38 MAP kinase activation is
required for mitochondrial events in the cell death cascade we
pretreated NPC with SB203580 or vehicle, exposed the cells to SNP for
7 h, and then examined levels of mitochondrial and cytosolic
cytochrome c by immunoblot analysis. SNP induced cytochrome
c release in cell pretreated with vehicle, but caused little
or no cytochrome c release in cells pretreated with SB203580
(Fig. 6A). SB203580 also
prevented activation of caspase-3 in NPC exposed to SNP (Fig. 6,
B and C). These data indicate that p38 MAP kinase
acts at a premitochondrial step in the apoptotic cascade triggered
by NO.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of p38 MAP kinase prevents nitric
oxide-induced release of cytochrome c and caspase
activation in neural progenitor cells. A, cells were
exposed for 7 h to vehicle (Con), 250 µM
SNP or 20 µM SB203580. Proteins in mitochondrial and
cytosolic fractions of the cells were then subjected to immunoblot
analysis using an antibody against cytochrome c.
B, confocal laser scanning microscope images showing
fluorescence corresponding to activated caspase-3 in cells in a control
culture, a culture that had been exposed to 250 µM SNP
for 7 h and culture that had been pretreated with 20 µM SB203580 and then exposed to 250 µM SNP
for 7 h. Note that SB203580 treatment largely prevented
SNP-induced caspase-3 activation. C, cells were pretreated
with vehicle or 20 µM SB203580 and then exposed to SNP
for the indicated time periods. Relative levels of activated caspase-3
were quantified. Values are the mean and S.E. of determinations made in
four to six cultures. p < 0.01 compared with the
corresponding value for cells exposed to SNP alone (ANOVA with Scheffe
post-hoc tests).
|
|
Bcl-2 is an anti-apoptotic protein that can prevent cell death by
suppressing oxyradical-mediated membrane damage, stabilizing mitochondrial membrane potential, and preventing release of cytochrome c (59, 60). To determine whether Bcl-2 could protect NPC
against NO-induced cell death, we transiently transfected C17.2 cells with an expression plasmid containing cDNA encoding Bcl-2. The transfection efficiency was ~30% as determined by co-transfection with a green fluorescent protein reporter plasmid (Fig.
7A). Immunoblot analysis
demonstrated a marked increase in levels of Bcl-2 protein in cells
24 h after transfection with the bcl-2 expression
plasmid (Fig. 7B). Control cultures were transfected with
GFP plasmid alone. Twenty-four hours after transfection, cells were
exposed to SNP, and 7 h later were fixed and stained with the
fluorescent DNA-binding dye propidium iodide. In control cultures
transfected with GFP alone, an identical percentage (~50%) of the
transfected cells (GFP+) and nontransfected cells
(GFP
) exhibited apoptotic nuclei (Fig. 7C). In
contrast, only 7% of the cells overexpressing Bcl-2 underwent
apoptosis when exposed to SNP. Bcl-2 may prevent apoptosis by
associating with mitochondrial membranes and preventing release of
cytochrome c. Consistent with this mechanisms of action of
Bcl-2, we found that cytochrome c release from mitochondria
did not occur after exposure to SNP in overexpressing Bcl-2 (data not
shown). Thus, Bcl-2 protects NPC against nitric oxide-mediated
apoptosis.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 7.
Overexpression of Bcl-2 protects neural
progenitor cells against nitric oxide-mediated death.
A, cells were co-transfected with plasmids for expression of
GFP and Bcl-2 (left) or GFP and empty vector
(right). 24 h later the cells were exposed to 500 µM SNP for 7 h and then stained with propidium
iodide. The micrographs show double-label fluorescence images of GFP
(cells overexpressing Bcl-2) and propidium iodide. Note that cells
transfected with the Bcl-2 expression plasmid are not killed by SNP,
whereas most untransfected cells (narrow arrows) and cells
transfected with empty vector (broad arrows) are killed
(showing condensed nuclei stained with propidium iodide). B,
immunoblot showing levels of Bcl-2 protein in cells transfected with
Bcl-2 expression plasmid (right lane) compared with control
cells transfected with empty vector (left lane). The cells
were harvested 24 h after transfection and each lane was loaded
with 50 µg of total cellular protein. C, cells were
transfected with empty vector or a Bcl-2 expression plasmid, and
24 h later were exposed to 500 µM SNP. Seven hours
later the percentages of GFP-negative untransfected cells, and
GFP-positive transfected cells, that were dead were quantified. Values
are the mean and S.E. of determinations made in at least six cultures.
**, p < 0.001 compared with each of the other values
(ANOVA with Scheffe post-hoc tests).
|
|
Because cells overexpressing Bcl-2 and cells pretreated with zVAD-fmk
plus SB 203580 exhibited similar resistance to NO-induced apoptosis, we
determined whether overexpression of Bcl-2 affected p38 MAP kinase
activation. To this end, we transfected cells with Bcl-2 expression
plasmid or empty vector as a control for 24 h and then treated the
cells with SNP for 1 or 4 h. Levels of phosphorylated p38 MAP
kinase in cell lysates were then assessed by immunoblot analysis.
Overexpression of Bcl-2 resulted in an attenuation of p38 MAP kinase
activation without affecting the total amount of p38 MAP kinase (Fig.
8).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 8.
Overexpression of Bcl-2 attenuates the
activation of p38 MAP kinase induced by SNP. A, cells
were transfected with Bcl-2 expression plasmid or empty vector and then
exposed to 500 µM SNP for the indicated time periods.
Cell lysates (50 µg of protein/lane) were subjected to immunoblot
analysis using antibodies against phospho-p38 MAP kinase or total p38
MAP kinase. B, data from densitometric analysis of
immunoblots (mean and S.E. from three separate experiments). **,
p < 0.01 compared with value for vector-transfected
cells (ANOVA with Scheffe post-hoc tests).
|
|
 |
DISCUSSION |
Death of NPC occurs during development of the nervous system (1,
9-11, 61), and is also believed to occur in populations of NPC located
in the dentate gyrus of the hippocampus (62-64) and the subventricular
zone (13) in the adult brain. In contrast to the considerable data
available on the cellular and molecular mechanisms that regulate the
survival of postmitotic neurons (65, 66), the mechanisms that determine
whether NPC live or die are largely unknown. The ability of NO to
induce apoptosis has been documented in previous studies of
non-neuronal cells (24), and may play roles in the deaths of neurons
that occur in a variety of neurological disorders (23, 67). Although
the present findings provide the first evidence that nitric oxide can
induce apoptosis of NPC, previous observations are consistent with a
role for nitric oxide in the regulation of the survival/death decision
of NPC and their immediate progeny. Nitric-oxide synthase is expressed in cells throughout the cerebral cortex, hippocampus, and other brain
regions during the highly proliferative period of brain development
(68). The neuronal isoform of nitric-oxide synthase is also expressed
in presumptive NPC in the subventricular zone and olfactory bulb of the
mature rodent brain (69, 70), and in cells immediately adjacent to NPC
in the adult subventricular zone (71). Thus, NPC are likely to be
exposed to nitric oxide in the developing and adult brain.
To determine whether excessive generation of NO can cause NPC death,
and to elucidate the underlying mechanisms, we employed C17.2 cells, a
clonal line of multipotent NPC. These cells have been extensively
characterized in previous studies in which it was shown that they can
differentiate into functional neurons and glial cells when transplanted
into the developing mouse cerebellum (48, 72). Another property of
C17.2 cells that is shared with endogenous NPC is their mitogenic
response to bFGF and EGF (4, 73, 74). The data obtained in the present
study allow the following conclusions regarding the regulation of C17.2
NPC survival by NO: 1) NO can induce apoptosis of NPC in a time- and
concentration-dependent manner. 2) NO induces apoptosis by
a mechanism involving mitochondrial dysfunction and release of
cytochrome c. 3) NO-induced death of NPC requires PARP
activation. 4) NO-induced death of NPC requires caspase activation. 5)
NO-induced death of NPC requires p38 MAP kinase activation, and p38 MAP
kinase acts at a site(s) upstream of mitochondrial alterations. 6)
Bcl-2 can attenuate p38 MAP kinase activation and can protect NPC
against NO-induced death. Previous studies in non-neural cells and
mature neurons suggest that NO triggers apoptosis by a mechanism
involving production of oxyradicals, resulting in oxidative damage to
DNA, activation of PARP, mitochondrial membrane permeability
transition, release of cytochrome c, and caspase activation
(26, 32, 57, 75-77). The latter mechanism appears to be operative in
NPC because treatment of the NPC with the PARP inhibitor
3-aminobenzamide and the caspase inhibitor zVAD-fmk significantly
attenuated SNP-induced cell death.
To gain further insight into the mechanism of NO-mediated death of NPC,
we examined the possible involvement of members of the MAP kinase
superfamily, because increasing evidence suggest they play important
roles in the cell survival/death decision in many different
physiological and pathological settings (78, 79). We observed that, in
contrast to p38 MAP kinase, JNK, ERK-1, and ERK-2 (80, 81) were not
activated in NPC exposed to nitric oxide. Each of the four kinases are
activated by simultaneous phosphorylation of threonine and tyrosine
residues by upstream dual-specificity kinases. However, the different
MAP kinase members are activated in response to different extracellular
stimuli and have different downstream targets, and thus serve different
roles in cellular responses. ERKs are activated by growth factors by means of a Ras-Raf-1-dependent cascade (82-85), whereas
JNK and p38 MAP kinase are activated by various cellular stressors
including UV irradiation, heat shock, and proinflammatory cytokines
(86-90). Our finding that NO selectively activates p38 MAP kinase
without affecting JNK indicates that p38 MAP kinase and JNK contribute to distinct signaling pathway of apoptosis. The latter interpretation is consistent with a recent report that NO can selectively activate p38
MAP kinase in neurons (47).
p38 MAP kinase has been associated with induction of apoptosis in
numerous cells types and in response to many different cellular stresses (54, 58, 91). However, activation of p38 MAP kinase may either
prevent cell death (92-94) or trigger apoptosis (47, 58, 95-97)
depending upon the cell type and specific death stimulus. We found that
the p38 MAP kinase inhibitor SB203580 was very effective in protecting
NPC against NO-mediated death, and that inhibiting both p38 MAP kinase
and caspases was more effective than inhibiting either enzyme alone.
The relationships between p38 MAP kinase and caspases are unclear. It
was recently reported that a p38 MAP kinase inhibitor can prevent
activation of caspases and apoptosis in neurons (98, 99) and can
block Bax translocation to mitochondria (47). Our data are consistent
with a site of action of p38 MAP kinase upstream of mitochondrial
changes and caspase activation (Fig. 9).
However, the additive effects of caspase and p38 MAP kinase inhibitors
in protecting NPC against NO-induced death suggests that at least some
activation of caspases may occur independently of p38 MAP kinase in
nitric oxide-induced NPC death.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 9.
Model showing pathways that mediate nitric
oxide-induced apoptosis of neural progenitor cells. Nitric oxide
induces activation of p38 MAP kinase by a mechanism that can be
inhibited by Bcl-2 and that likely involves oxidative stress. p38 MAP
kinase induces mitochondrial membrane alterations resulting in release
of cytochrome c and activation of caspases. See text for
discussion.
|
|
We found that the p38 MAP kinase inhibitor attenuated NO-induced
cytochrome c release and caspase activation, demonstrating an action of this kinase upstream of mitochondrial alterations. Previous studies have provided evidence that p38 MAP kinase is activated by oxidative stress, including the oxidative stress induced
by nitric oxide, and this mechanism is also likely to occur in NPC. The
ability of Bcl-2 to attenuate nitric oxide-induced activation of p38
MAP kinase in NPC is consistent with a role for oxidative stress in
that Bcl-2 has been shown to function in antioxidant pathways (100) and
can suppress oxidative damage to cell membranes (60). On the
other hand, it has been proposed that Bcl-2 can prevent apoptosis by
heterodimerizing with Bax and modulating pore formation in
mitochondrial membranes (102-104). A similar mechanism of protection
of NPC against nitric oxide-induced death is likely because NO-induced
cytochrome c release was suppressed in NPC overexpressing
Bcl-2. However, we also found that Bcl-2 overexpression attenuated the
activation of p38 MAP kinase suggesting that, in addition to being
activated upstream of mitochondrial changes, p38 MAP kinase may also be
activated in response to mitochondrial changes. Bcl-2 is expressed at
high levels during neurogenesis in the developing brain (105), rodent
subventricular zone cells positive for NPC markers also express Bcl-2
in vivo (106), and it has been reported that Bcl-2 is
present in NPC from the subventricular zone of the adult human brain
(101). It is therefore conceivable that signals that regulate NO
production and Bcl-2 expression might interact in the regulation of
survival of NPC in the developing and adult nervous system. Our data
suggest a role for nitric oxide in regulating survival of the NPC,
although further work will be required to establish the specific roles
of nitric oxide in determining NPC fate in vivo.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Laboratory of
Neurosciences, National Institute on Aging Gerontology Research Center
4F02, 5600 Nathan Shock Dr., Baltimore, MD 21224. Tel.: 410-558-8463;
Fax: 410-558-8465; E-mail: mattsonm@grc.nia.nih.gov.
Published, JBC Papers in Press, September 12, 2001, DOI 10.1074/jbc.M107698200
 |
ABBREVIATIONS |
The abbreviations used are:
NPC, neural
progenitor cells;
JNK, c-Jun N-terminal kinase;
MAP, mitogen-activated
protein;
NO, nitric oxide;
PARP, poly(ADP-ribose) polymerase;
SNP, sodium nitroprusside;
PBS, phosphate-buffered saline;
ERK, extracellular regulated kinase.
 |
REFERENCES |
| 1.
|
Kuan, C. Y.,
Roth, K. A.,
Flavell, R. A.,
and Rakic, P.
(2000)
Trends Neurosci.
23,
291-297[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Morshead, C. M.,
Craig, C. G.,
and van der Kooy, D.
(1998)
Development
125,
2251-2261[Abstract]
|
| 3.
|
Gage, F. H.
(2000)
Science
287,
1433-1438[Abstract/Free Full Text]
|
| 4.
|
Kitchens, D. L.,
Snyder, E. Y.,
and Gottlieb, D. I.
(1994)
J. Neurobiol.
25,
797-807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Artavanis-Tsakonis, S.,
Matsuno, K.,
and Fortini, M. E.
(1995)
Science
268,
225-231[Abstract/Free Full Text]
|
| 6.
|
Spana, E. P.,
and Doe, C. Q.
(1996)
Neuron
17,
21-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Guo, M.,
Jan, L. Y.,
and Jan, Y. N.
(1996)
Neuron
17,
27-41[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Zilian, O.,
Saner, C.,
Hagedorn, L.,
Lee, H.,
Sauberli, E.,
Suter, U.,
Sommer, L.,
and Aguet, M.
(2001)
Curr. Biol.
11,
494-501[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Homma, S.,
Yaginuma, H.,
and Oppenheim, R. W.
(1994)
J. Comp. Neurol.
345,
377-395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Slack, R. S.,
Skerjanc, I. S.,
Lach, B.,
Craig, J.,
Jardine, K.,
and McBurney, M. W.
(1995)
J. Cell Biol.
129,
779-788[Abstract/Free Full Text]
|
| 11.
|
Rakic, S.,
and Zecevic, N.
(2000)
Eur. J. Neurosci.
12,
2721-2734[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Hagedorn, L.,
Floris, J.,
Suter, U.,
and Sommer, L.
(2000)
Dev. Biol.
228,
57-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Levison, S. W.,
Rothstein, R. P.,
Brazel, C. Y.,
Young, G. M.,
and Albrecht, P. J.
(2000)
Dev. Neurosci.
22,
106-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Frank, K. M.,
Sharpless, N. E.,
Gao, Y.,
Sekiguchi, J. M.,
Ferguson, D. O.,
Zhu, C.,
Manis, J. P.,
Horner, J.,
DePinho, R. A.,
and Alt, F. W.
(2000)
Mol. Cell
5,
993-1002[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Honarpour, N.,
Du, C.,
Richardson, J. A.,
Hammer, R. E.,
Wang, X.,
and Herz, J.
(2000)
Dev. Biol.
218,
248-258[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
D'Sa-Eipper, C.,
and Roth, K. A.
(2000)
Dev. Neurosci.
22,
116-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Holscher, C.
(1997)
Trends Neurosci.
20,
298-303[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Dawson, V. L.,
and Dawson, T. M.
(1998)
Prog. Brain Res.
118,
215-229[Medline]
[Order article via Infotrieve]
|
| 19.
|
Phung, Y. T.,
Bekker, J. M.,
Hallmark, O. G.,
and Black, S. M.
(1999)
Mol. Brain Res.
64,
165-178[Medline]
[Order article via Infotrieve]
|
| 20.
|
Rialas, C. M.,
Nomizu, M.,
Patterson, M.,
Kleinman, H. K.,
Weston, C. A.,
and Weeks, B. S.
(2000)
Exp. Cell Res.
260,
268-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Ogilvie, P.,
Schilling, K.,
Billingsley, M. L.,
and Schmidt, H. H.
(1995)
FASEB J.
9,
799-806[Abstract]
|
| 22.
|
Contestabile, A.
(2000)
Brain Res. Rev.
32,
476-509[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Leist, M.,
Volbracht, C.,
Kuhnle, S.,
Fava, E.,
Ferrando-May, E.,
and Nicotera, P.
(1997)
Mol. Med.
3,
750-764[Medline]
[Order article via Infotrieve]
|
| 24.
|
Brune, B.,
von Knethen, A.,
and Sandau, K. B.
(1999)
Cell Death Differ.
6,
969-975[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Uehara, T.,
Kikuchi, Y.,
and Nomura, Y.
(1999)
J. Neurochem.
72,
196-205[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Pieper, A. A.,
Blackshaw, S.,
Clements, E. E.,
Brat, D. J.,
Krug, D. K.,
White, A. J.,
Pinto-Garcia, P.,
Favit, A.,
Conover, J. R.,
Snyder, S. H.,
and Verma, A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
1845-1850[Abstract/Free Full Text]
|
| 27.
|
Calabrese, V.,
Bates, T. E.,
and Stella, A. M.
(2000)
Neurochem. Res.
25,
1315-1341[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Huang, Z.,
Huang, P. L.,
Panahian, N.,
Dalkara, T.,
Fishman, M. C.,
and Moskowitz, M. A.
(1994)
Science
265,
1883-1885[Abstract/Free Full Text]
|
| 29.
|
Dawson, V. L.,
Kizushi, V. M.,
Huang, P. L.,
Snyder, S. H.,
and Dawson, T. M.
(1996)
J. Neurosci.
16,
2479-2487[Abstract/Free Full Text]
|
| 30.
|
Ayata, C.,
Ayata, G.,
Hara, H.,
Matthews, R. T.,
Beal, M. F.,
Ferrante, R. J.,
Endres, M.,
Kim, A.,
Christie, R. H.,
Waeber, C.,
Huang, P. L.,
Hyman, B. T.,
and Moskowitz, M. A.
(1997)
J. Neurosci.
17,
6908-6917[Abstract/Free Full Text]
|
| 31.
|
Dawson, V. L.,
Dawson, T. M.,
London, E. D.,
Bredt, D. S.,
and Snyder, S. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
6368-6871[Abstract/Free Full Text]
|
| 32.
|
Beckman, J. S.,
Beckman, T. W.,
Chen, J.,
Marshall, P. A.,
and Freeman, B. A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1620-1624[Abstract/Free Full Text]
|
| 33.
|
Beckman, J. S.,
and Crow, J. P.
(1993)
Biochem. Soc. Trans.
21,
330-334[Medline]
[Order article via Infotrieve]
|
| 34.
|
Xia, Y.,
Dawson, V. L.,
Dawson, T. M.,
Snyder, S. H.,
and Zweier, J. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6770-6774[Abstract/Free Full Text]
|
| 35.
|
Ischiropoulos, H.
(1998)
Arch. Biochem. Biophys.
356,
1-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Bartsch, H.,
and Nair, J.
(2000)
Eur. J. Cancer
36,
1229-1234
|
| 37.
|
Bloodsworth, A.,
O'Donnell, V. B.,
and Freeman, B. A.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
1707-1715[Abstract/Free Full Text]
|
| 38.
|
Zhang, J.,
Dawson, V. L.,
Dawson, T. M.,
and Snyder, S. H.
(1994)
Science
263,
687-689[Abstract/Free Full Text]
|
| 39.
|
Kluck, R. M.,
Bossy-Wetzel, E.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
Science
275,
1132-1136[Abstract/Free Full Text]
|
| 40.
|
Yang, J.,
Liu, X.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J.,
Peng, T. I.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1132[Abstract/Free Full Text]
|
| 41.
|
Tamatani, M.,
Ogawa, S.,
Nunez, G.,
and Tohyama, M.
(1998)
Cell Death Differ.
5,
911-919[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Tamatani, M.,
Ogawa, S.,
Niitsu, Y.,
and Tohyama, M.
(1998b)
J. Neurochem.
71,
1588-1596[Medline]
[Order article via Infotrieve]
|
| 43.
|
Jun, C. D.,
Oh, C. D.,
Kwak, H. J.,
Pae, H. O.,
Yoo, J. C.,
Choi, B. M.,
Chun, J. S.,
Park, R. K.,
and Chung, H. T.
(1999)
J. Immunol.
162,
3395-3401[Abstract/Free Full Text]
|
| 44.
|
Davis, R. J.
(2000)
Cell
103,
239-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Franklin, R. A.,
and McCubrey, J. A.
(2000)
Leukemia
14,
2019-2034[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Mielke, K.,
and Herdegen, T.
(2000)
Prog. Neurobiol.
61,
45-60[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Ghatan, S.,
Larner, S.,
Kinoshita, Y.,
Hetman, M.,
Patel, L.,
Xia, Z.,
Youle, R. J.,
and Morrison, R. S.
(2000)
J. Cell Biol.
150,
335-347[Abstract/Free Full Text]
|
| 48.
|
Snyder, E. Y.,
Deitcher, D. L.,
Walsh, C.,
Arnold-Aldea, S.,
Hartwieg, E. A.,
and Cepko, C. L.
(1992)
Cell
68,
33-51[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Snyder, E. Y.,
Yoon, C.,
Flax, J. D.,
and Macklis, J. D.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11663-11668[Abstract/Free Full Text]
|
| 50.
|
Mattson, M. P.,
Partin, J.,
and Begley, J. G.
(1998)
Brain Res.
807,
167-176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Budihardjo, I.,
Oliver, H.,
Lutter, M.,
Luo, X.,
and Wang, X.
(1999)
Annu. Rev. Cell Dev. Biol.
15,
269-290[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Rincon, M.,
Flavell, R. A.,
and Davis, R. A.
(2000)
Free Radic. Biol. Med.
28,
1328-1337[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Rosini, P.,
De Chiara, G.,
Lucibello, M.,
Garaci, E.,
Cozzolino, F.,
and Torcia, M.
(2000)
Biochem. Biophys. Res. Commun.
278,
753-759[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Xia, Z.,
Dickens, M.,
Raigeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331[Abstract/Free Full Text]
|
| 55.
|
Kikuchi, M.,
Tenneti, L.,
and Lipton, S. A.
(2000)
J. Neurosci.
20,
5037-5044[Abstract/Free Full Text]
|
| 56.
|
Didier, C.,
Emonet-Piccardi, N.,
Beani, J. C.,
Cadet, J.,
and Richard, M. J.
(1999)
FASEB J.
13,
1817-1824[Abstract/Free Full Text]
|
| 57.
|
Kruman, I. I.,
Culmsee, C.,
Chan, S. L.,
Kruman, Y.,
Guo, Z.,
Penix, L.,
and Mattson, M. P.
(2000)
J. Neurosci.
20,
6920-6926[Abstract/Free Full Text]
|
| 58.
|
Schwenger, P.,
Bellosta, P.,
Vietor, I.,
Basilico, C.,
Skolnik, E. Y.,
and Vilcek, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2869-2873[Abstract/Free Full Text]
|
| 59.
|
Desagher, S.,
and Martinou, J. C.
(2000)
Trends Cell Biol.
10,
369-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Bruce-Keller, A. J.,
Begley, J. G.,
Fu, W.,
Butterfield, D. A.,
Bredesen, D. E.,
Hutchins, J. B.,
Hensley, K.,
and Mattson, M. P.
(1998)
J. Neurochem.
70,
31-39[Medline]
[Order article via Infotrieve]
|
| 61.
|
Graham, A.,
Heyman, I.,
and Lumsden, A.
(1993)
Development
119,
233-245[Abstract]
|
| 62.
|
Young, D.,
Lawlor, P. A.,
Leone, P.,
Dragunow, M.,
and During, M. J.
(1999)
Nature Med.
5,
448-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Biebl, M.,
Cooper, C. M.,
Winkler, J.,
and Kuhn, H. G.
(2000)
Neurosci. Lett.
291,
17-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Lee, J.,
Duan, W.,
Long, J. M.,
Ingram, D. K.,
and Mattson, M. P.
(2000)
J. Mol. Neurosci.
15,
99-108[Medline]
[Order article via Infotrieve]
|
| 65.
|
Weller, M.,
Schulz, J. B.,
Wullner, U.,
Loschmann, P. A.,
Klockgether, T.,
and Dichgans, J.
(1997)
J. Neural Transm. Suppl.
50,
115-123[Medline]
[Order article via Infotrieve]
|
| 66.
|
Mattson, M. P.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
120-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Heales, S. J.,
Bolanos, J. P.,
Stewart, V. C.,
Brookes, P. S.,
Land, J. M.,
and Clark, J. B.
(1999)
Biochim. Biophys. Acta
1410,
215-228[Medline]
[Order article via Infotrieve]
|
| 68.
|
Giuili, G.,
Luzi, A.,
Poyard, M.,
and Guellaen, G.
(1994)
Dev. Brain Res.
81,
269-283[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Samama, B.,
and Boehm, N.
(1996)
Dev. Brain Res.
96,
192-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Santacana, M.,
Uttenthal, L. O.,
Bentura, M. L.,
Fernandez, A. P.,
Serrano, J.,
Martinez de Velasco, J.,
Alonso, D.,
Martinez-Murillo, R.,
and Rodrigo, J.
(1998)
Dev. Brain Res.
111,
205-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Moreno-Lopez, B.,
Noval, J. A.,
Gonzalez-Bonet, L. G.,
and Estrada, C.
(2000)
Brain Res.
869,
244-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 72.
|
Ryder, E. F.,
Snyder, E. Y.,
and Cepko, C. L.
(1990)
J. Neurobiol.
21,
356-375[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Reynolds, B. A.,
and Weiss, S.
(1992)
Science
255,
1707-1710[Abstract/Free Full Text]
|
| 74.
|
Kilpatrick, T. J.,
and Bartlett, P. F.
(1993)
Neuron
10,
255-265[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Messmer, U. K.,
Reimer, D. M.,
Reed, J. C.,
and Brune, B.
(1996)
FEBS Lett.
384,
162-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Scovassi, A. I.,
and Poirier, G. G.
(1999)
Mol. Cell. Biochem.
199,
125-137[CrossRef][Medline]
[Order article vi |